Stock Market News
Cambridge Cognition expects 'significant' revenue from new contract
Cambridge Cognition has been awarded a major pharmaceutical clinical trial contract and a digital health catalyst grant from Innovate UK, collectively bringing a further £2.3m to the digital neuroscience company.
The new clinical trial contract, originally expected in the last quarter of 2017, was seen as "significant contract" win for Cambridge Cognition. The multi-nation phase four clinical study is with an unnamed "leading pharmaceutical company" and is set to make a "material impact" on the company's 2018 and 2019 revenues.
Cambridge Cognition will deliver the study's cognitive assessments, patient-reported outcomes and clinician-reported outcomes to its client via its CANTAB Connect cloud software.
Separately, the Innovate UK grant will be used by Cambridge Cognition to fund a "pioneering new programme to develop a non-invasive digital biomarker to better predict who will benefit from a new type of personalised medication in schizophrenia."
In developing a new digital biomarker, the Cambridge Cognition aims to demonstrate the ability to identify schizophrenia patients who will benefit from personalised medicines targeting a particular aspect of brain function and find people in the general population who are at risk, in order to help prevent schizophrenia cases in future.
Schizophrenia affects more than 21m people worldwide and is associated with health and societal costs in the vicinity of £12bn per year in the UK and $60bn per year in the US.
Chief executive officer Dr Steven Powell said the grant will enable the company to "work even closer with our partners in the pharmaceutical industry to enhance their drug development pipelines and provide first in class personalised medicines" and that the clinical contract was expected to benefit future revenues "significantly".
As of 0850 GMT, shares had gained 16.40% to 116.40p.
The new clinical trial contract, originally expected in the last quarter of 2017, was seen as "significant contract" win for Cambridge Cognition. The multi-nation phase four clinical study is with an unnamed "leading pharmaceutical company" and is set to make a "material impact" on the company's 2018 and 2019 revenues.
Cambridge Cognition will deliver the study's cognitive assessments, patient-reported outcomes and clinician-reported outcomes to its client via its CANTAB Connect cloud software.
Separately, the Innovate UK grant will be used by Cambridge Cognition to fund a "pioneering new programme to develop a non-invasive digital biomarker to better predict who will benefit from a new type of personalised medication in schizophrenia."
In developing a new digital biomarker, the Cambridge Cognition aims to demonstrate the ability to identify schizophrenia patients who will benefit from personalised medicines targeting a particular aspect of brain function and find people in the general population who are at risk, in order to help prevent schizophrenia cases in future.
Schizophrenia affects more than 21m people worldwide and is associated with health and societal costs in the vicinity of £12bn per year in the UK and $60bn per year in the US.
Chief executive officer Dr Steven Powell said the grant will enable the company to "work even closer with our partners in the pharmaceutical industry to enhance their drug development pipelines and provide first in class personalised medicines" and that the clinical contract was expected to benefit future revenues "significantly".
As of 0850 GMT, shares had gained 16.40% to 116.40p.
Related share prices |
---|
Cambridge Cognition Holdings (COG) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price